LY4006896 Phase 1 Parkinson's Disease Trial

Overview

LY4006896 is a novel therapeutic candidate developed by [Eli Lilly and Company](https://www.lilly.com) currently undergoing evaluation in a Phase 1 clinical trial for [Parkinson's disease](/diseases/parkinsons-disease)[@kalia_2015]. This trial represents Eli Lilly's strategic entry into Parkinson's disease drug development, expanding beyond their established Alzheimer's disease pipeline["@lilly_neuro"].

Overview

LY4006896 is a novel therapeutic candidate developed by [Eli Lilly and Company](https://www.lilly.com) currently undergoing evaluation in a Phase 1 clinical trial for [Parkinson's disease](/diseases/parkinsons-disease)[@kalia_2015]. This trial represents Eli Lilly's strategic entry into Parkinson's disease drug development, expanding beyond their established Alzheimer's disease pipeline["@lilly_neuro"].

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide["@jankovic_2020"]. The disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the classic motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability["@bargmann_2013"].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT06809400 |
| Sponsor | Eli Lilly and Company |
| Phase | Phase 1 |
| Status | Recruiting |
| Study Type | Interventional |
| Indication | Parkinson's Disease |
| Start Date | 2024 |

Trial Design

Phase 1 trials represent the first human testing of a new therapeutic compound and primarily focus on safety and tolerability[@postma_2024]. The design typically includes:

Dose-Escalation Phase

• Single ascending dose (SAD) cohort
• Multiple ascending dose (MAD) cohort
• Safety monitoring at each dose level
• Pharmacokinetic sampling

Study Objectives

• Evaluate safety and tolerability in Parkinson's disease patients
• Characterize pharmacokinetic profile
• Identify maximum tolerated dose (MTD)
• Assess preliminary pharmacodynamic signals

Mechanism of Action

While the specific molecular mechanism of LY4006896 remains proprietary, Eli Lilly's neuroscience division has been exploring several pathways relevant to Parkinson's disease pathogenesis:

Alpha-Synuclein Targeting

• Monoclonal antibodies against alpha-synuclein
• Small molecules inhibiting aggregation
• Gene therapy approaches

Neuroprotection

• Anti-apoptotic signaling modulation
• Growth factor support
• Cellular stress response enhancement

Mitochondrial Function

• Complex I activity restoration
• Oxidative stress reduction
• Mitochondrial dynamics normalization

Neuroinflammation Modulation

• Microglial activation inhibition
• Cytokine blockade
• Complement system modulation

Clinical Development Context

Eli Lilly's Neuroscience Portfolio

Eli Lilly has built a significant neuroscience pipeline targeting neurodegenerative diseases:

| Compound | Target | Indication | Status |
|----------|--------|------------|--------|
| Donanemab | Amyloid-beta | Alzheimer's Disease | Approved |
| Remternetug | Amyloid-beta | Alzheimer's Disease | Phase 3 |
| LY4006896 | Unknown | Parkinson's Disease | Phase 1 |

Parkinson's Disease Therapeutic Landscape

The Parkinson's disease treatment landscape includes several approaches[@dexheimer_2023]:

Disease-Modifying Therapies (Investigational)

• Alpha-synuclein antibodies (cinpanemab, prasinezumab)
• LRRK2 inhibitors (direnox, DNL151)
• GBA modulators
• Mitochondrial protectants

Symptomatic Treatments

• Dopamine agonists
• MAO-B inhibitors
• Levodopa/carbidopa
• Deep brain stimulation

Significance for Parkinson's Disease Research

Unmet Medical Needs

Current Parkinson's disease treatments provide symptomatic relief but do not slow or halt disease progression. LY4006896 represents an attempt to develop disease-modifying therapies addressing:

Clinical Trial Importance

Early-phase trials like NCT06809400 are critical for:

• Validating novel therapeutic targets in humans
• Establishing safety profiles for new chemical entities
• Providing pharmacokinetic data for future development
• Identifying patient populations most likely to benefit

Related Mechanisms and Pathways

Parkinson's Disease Pathogenesis

• [Alpha-synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Lewy Body Formation](/mechanisms/lewy-body-formation)

Related Therapeutic Approaches

• [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors)
• [Alpha-synuclein Antibodies](/therapeutics/alpha-synuclein-antibodies)
• [GDNF Gene Therapy](/therapeutics/gdnf-gene-therapy)

Related Clinical Trials

• [Buntanetap Phase 3 PD Trial](/clinical-trials/buntanetap-phase3-pd-nct07284784)
• [Nilotinib Parkinson's Trial](/clinical-trials/nilotinib-parkinsons-nct03744468)
• [LY4006896 Phase 1 PD](/clinical-trials/ly4006896-phase-1-pd-nct06809400)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Eli Lilly](/companies/eli-lilly)
• [Clinical Trials](/clinical-trials)
• [Parkinson's Disease Clinical Trials](/clinical-trials/parkinsons-disease-clinical-trials)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [LRRK2](/genes/lrrk2)
• [GBA](/genes/gba)

External Links

• [ClinicalTrials.gov NCT06809400](https://clinicaltrials.gov/study/NCT06809400)
• [Eli Lilly Neuroscience Pipeline](https://www.lilly.com)

References